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Abstract
Currently in clinic, people use hematoxylin and eosin stain (H&E stain) and immunohistochemistry methods to identify the
generation and genre of cancers for human pathological samples. Since these methods are inaccurate and time consuming,
developing a rapid and accurate method to detect cancer is urgently demanded. In our study, binding peptides for lung
cancer cell line A549 were identified using bacteria surface display method. With those binding peptides for A549 cells on
the surface, the fluorescent bacteria (Escherichia coli with stably expressed green fluorescent protein) were served as specific
detecting reagents for the diagnosis of cancers. The binding activity of peptide-fluorescent bacteria complex was confirmed
by detached cancer cells, attached cancer cells and mice tumor xenograft samples. A unique fixation method was
developed for peptide-bacteria complex in order to make this complex more feasible for the clinic use. This peptide-
fluorescent bacteria complex has great potential to become a new diagnostic tool for clinical application.
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Introduction
With the development of new techniques regarding diagnosis
and treatment for cancers, the mortality rate of cancer patients has
decreased in the past decades. However, the aim to cure cancers is
still far from reaching. Currently, the key points to increase the
cure rate and life quality of cancer patients are earlier and accurate
diagnosis and effective treatment for such malignant diseases. The
application of sensitive luminescent reagents and targeting
molecules for cancer cells provides useful tools for accurate
diagnosis and effective treatment for cancers. Novel luminescent
materials such as quantum dots [1], upconversion nanomaterials
[2] and nanobubbles [3] have been attempted to apply to the
cancer imaging systems. Various molecules such as antibodies [4],
peptides [5,6] and aptamers [7] have been used as targeting
molecules for cancer diagnosis and therapy. Although there are
some progress for the development of luminescent materials and
targeting molecules, effective systems for cancer diagnosis and
therapy have not been fully established. Earlier and more accurate
diagnosis methods combining targeting molecules with robust
imaging molecules attract more and more researchers’ interest [8].
Our study intends to establish a novel system which includes
targeting peptides and fluorescent bacteria for the accurate
diagnosis of cancers. Targeting peptides could be screened and
identified by bacteria surface display method developed in the
1990s [9,10]. Using the fluorescence activated cell sorter (FACS),
various peptides with specific binding activity have been obtained
in a high throughput way with bacteria display method [11,12].
Currently, with this method, the targeting peptides for breast
cancer cells [13] and substrate peptides for proteinase [14] have
been identified. In our study, with the identification of the specific
binding peptides for lung cancer A549 cells, a new technique for
detecting lung cancer cells using peptide-fluorescent bacteria
system would be established. Furthermore, peptide-fluorescent
bacteria system could be used as the diagnostic reagent in clinical
application for cancer patients in future.
Materials and Methods
1. Cell Culture and Materials
Human lung carcinoma cell lines (A549 cells and H460 cells),
human breast adenocarcinoma cell line (MCF-7), human hepato-
cellular carcinoma cell line (HepG-2), human cervical carcinoma
cell line (HeLa) and human laryngeal carcinoma cell line (Hep-2)
were used in this study. These cell lines were grown in RPMI-1640
(Hyclone Corp., USA) and human lung fibroblast cells (HLF) were
cultured in Dulbecco’s Modified Eagle Medium (Hyclone Corp.,
USA) in a 5% CO2 humidified incubator at 37uC. The medium
was supplemented with 10% fetal bovine serum (FBS) (Hyclone
Corp., USA) and 1% penicillin/streptomycin (China National
Medicine Corp., China). A549, H460 and HLF cells were kind
gifts from Dr Biliang Zhang [15,16] (Guangzhou institutes of
biomedicine and health, CAS, China). MCF-7, HepG-2, HeLa
and Hep-2 cells were kind gifts from Dr Haiyan Liu [17,18] (The
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Cyrus Tang Hematology Center, Soochow University, China).
The other chemical agents in this study were purchased from the
China National Medicine Corporation.
2. Screening of Binding Monoclonal Peptide-fluorescent
Bacteria with A549 cells
The bacterial peptide library of E. coli used in this study was a
gift from Patrick S. Daugherty in the Department of Chemical
Engineering, University of California, Santa Barbara. In this
bacterial peptide library, every E. coli surface presented 13-mer
Figure 1. The process of screening and enriching the binding peptide library for cancer cells with bacteria surface display methods.
(A) Schematic representation of peptides screening and selection with bacterial display library. 1. Constructed the library by transforming plasmids
into E.coli MC1061; 2. Discarded the bacteria binding with normal cells after pre-incubation; 3. Incubated the mixture of cancer cells and residual
bacteria; 4. Analyzed the binding effect of cancer cells with bacteria using FACS; 5. Sorted the binding bacteria to cancer cells by flow cytometry and
cultured the binding bacteria in medium; 6. Performed the next round binding bacteria screening; 7. Isolated the binding bacteria to cancer cells and
sequenced the peptides displayed on the surface of the bacteria. (B) The progress of enrichment of bacteria binding with cancer cells by FACS in 6
screening rounds.
doi:10.1371/journal.pone.0054467.g001
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peptide (X2CX7CX2) fusing in the second extracellular loop of
the circularly permuted outer membrane protein OmpX (CPX)
[13], in which expressed peptides and green fluorescent protein
(GFP) were induced by the addition of L-(+)-arabinose (0.02% w/
v) to a log-phase culture [13,19].
Frozen aliquots of 16109 bacteria were thawed and cultivated
overnight in super optimal broth (SOB) at 37uC and supplemented
with 34 mg/ml chloramphenicol (CM) and 0.2% (w/v) D-(+)-
glucose. The next day, bacteria were subcultured at 1:50 in
Lysogeny broth (LB) medium supplemented with 34 mg/ml CM
for 2 h at 37uC and induced by 0.02% (w/v) L-(+)-arabinose for
1 h at room temperature to ensure GFP and peptides expressed in
bacteria. After cultured (48 h post-seeding) A549 and HLF cells
were harvested by trypsinisation and resuspended in tubes. 107
HLF cells were co-incubated with 100-fold excess bacterial cells
for 45 min on an inversion shaker at 4uC. Cell suspensions were
centrifuged at 1000 rpm for 5 min at 4uC and the supernatant was
collected. This procedure might be repeated for another time due
to the increased non-specific binding events occurred for HLF
cells. The supernatant was co-incubated with 107 A549 cells for
45 min on an inversion shaker at 4uC and cell suspensions were
centrifuged at 1000 rpm for 5 min at 4uC and then washed three
times with PBS. The sediment was resuspended with 5 ml cold
PBS and immediately analyzed by FACS (BD FACS Aria II, BD
Corp. USA). The sorting gate in the FACS experiment was set
based on the fluorescent signals of negative control samples. Once
the fluorescence settings had been optimized for the negative
control, an appropriate sort gate was drawn for sorting the library
based on fluorescence. A sort gate was drawn to exclude as much
of the negative control as possible while still capturing positive
events in the library [13].The green fluorescent cells were gated for
sorting because if peptides which were on the surface of green
fluorescent bacteria could bind with A549 cells and the green
fluorescent signals of cells would increase. At least 105 events were
recorded and the tumor cells with increased green fluorescent
signals and dropped into the orange gate were collected with
FACS. The collected cells were cultured overnight in SOB
containing 0.2% D-(+)-glucose and 34 mg/ml CM. Bacteria
binding with cancer cells specifically were amplified for the next
round of screening. From the next round, 106 cells were enough
for FACS analysis and sorting. Until the fluorescent signal of
tumor cells stop increasing in sequentially two rounds, procedure
of screening for binding peptides was terminated. Selected bacteria
with binding peptides were cultured on the LB medium plate
containing 1% agar and 34 mg/ml CM. After cultured for 24 h at
37uC, monoclonal peptide-fluorescent bacteria were picked and
cultured in 5 ml SOB containing 0.2% (m/v) D-(+)-glucose and
34 mg/ml CM at 37uC overnight. The next day, the binding
activity of individual clones was examined by measuring the GFP
fluorescent signals of cells after A549 cells incubated with those
monoclonal peptide-fluorescent bacteria. The sequences of bind-
ing peptides on the surface of monoclonal peptide-fluorescent
bacteria were obtained by sending out those bacteria to Sangon
Biotech Co., Ltd. Shanghai, China for sequencing.
Figure 2. FACS results of selected monoclonal peptide-fluorescent bacteria binding with A549 cells and HLF cells. The binding
fraction of A549 cells with bacteria (show in the orange gate) was 80% and that of HLF cells was 0.4%.
doi:10.1371/journal.pone.0054467.g002
Table 1. Sequences of peptides.
Sequence of peptides Binding Rate Frequency
1 WFCSWYGGDTCVQ 80% 42
2 WKCTKYVCVL 40% 11
3 LNCSTKSLGYCVW 36% 2
4 WMCMTSPSRMCRN 10% 2
5 GYCEHTRMMLCQF 41% 1
6 GRCRLNGDCYCVR 9% 1
7 NSCTREQGVECGN 8% 1
Sequences and binding rates of different peptides with A549 cells. Peptides
were ordered by frequency in experiments.
doi:10.1371/journal.pone.0054467.t001
Fluorescent Bacteria in Cancer Diagnosis
PLOS ONE | www.plosone.org 3 January 2013 | Volume 8 | Issue 1 | e54467
Fluorescent Bacteria in Cancer Diagnosis
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e54467
3. Characterization of Binding Specificity and the
Efficiency between Peptide-fluorescent Bacteria and Cells
The experiments were performed on both attached and
detached cells. The fluorescence microscopy experiment was
firstly carried out to examine the binding specificity of monoclonal
peptide-fluorescent bacteria with attached cells. A549 cells, HLF
cells, H460 cells, MCF-7 cells, Hep-2 cells, HepG-2 cells and
HeLa cells (36105) were plated in 12-well cell culture plates one
day before the experiment. After induction, 100 ml of bacteria
suspension(<86107) in 1 ml of PBS were incubated with all kinds
of cells at room temperature which has been proved to ensure
proteins on the surface of cells expressed normally during the
incubation [13] for 45 min and were washed three times by PBS.
Cells were photographed with fluorescence microscopy (Nikon Ti,
Nikon Corp. Japan) to confirm the binding activity of monoclonal
peptide-fluorescent bacteria with cells. The binding activity
between monoclonal peptide-fluorescent bacteria with detached
cells was examined by flow cytometry. The procedure of
examining the binding activity of peptide-fluorescent bacteria is
similar to that of screening the binding peptides with cells.
4. Attempt of Maintaining Bacteria Binding Activity with
Various Fixation Methods
Fixation was done with different fixation reagents (ethanol [20],
methanol [21], acetone [22] and 4% paraformaldehyde [23]).
After centrifuged at 5000 rpm for 5 min, the supernatant was
removed and the bacteria were fixed in the fixation reagents for
20 min at room temperature. The excess fixation reagents were
removed and the fixed bacteria were suspended by PBS and stored
at 4uC.
Flow cytometry analysis and fluorescence microscopy experi-
ments were performed as indicated previously to examine the
binding activity of fixed bacteria with cells. Compared with fresh
monoclonal peptide-fluorescent bacteria, the ratio of fixed bacteria
to cells varied from 100:1 to 500:1 to obtain obvious and detected
fluorescent signals in cells. Normally, after bacteria were fixed, the
green fluorescent signals of bacteria decreased at certain extent.
To examining whether the binding activity of fixed bacteria with
cells was depended on time, fluorescence microscopy and FACS
analyses were carried out repeatedly at day 1, day 7 and day 30
after fixation.
5. Examination of Binding Activity of Peptide-fluorescent
Bacteria System with Tumor Tissue of Mice Xenograft
Binding experiment was performed on paraffin-embedded
tissue. A549 mice tumor xenograft samples on paraffin slides
were kind gifts from Dr Laura Cerchia and Dr Vittorio De
Franciscis (Istituto di Endocrinologia ed Oncologia Sperimentale,
CNR, Naples, Italy). The related paper about samples preparation
has already been published in the PLos One journal [24]. The
dewaxing procedure for the paraffin samples was done following
the accepted procedure [25]. 16106 (in 100 ml) fresh peptide-
bacteria and 56106 fixed peptide-bacteria were incubated
separately with paraffin tumor sections for 1 h at room temper-
ature. After washing with PBS three times, tumor sections were
observed under a Nikon A1R confocal laser scanning microscope
(Nikon Corp. Japan).
Results
1. Enrichment of Specific Binding Peptides Library for
A549 cells
In order to isolate cell specific binding ligands for a given tumor
cell phenotype we decided to set up a model system including
normal (non-tumor) cell line (HLF) and lung carcinoma cell line
(A549). HLF cells worked for counterselection in screening
process. A 13-mer library with cysteine restrained peptides was
utilized for selection of binding peptides against intact cells
(Figure 1A). At each round of A549 cells selection step one or two
counterselection steps against HLF cells were performed. During
the selection process, we progressively increased the selective
pressure by changing incubation condition, washing condition and
area of gate in FACS. During round 6 and 7, the ratio of green
fluorescent cells to whole cells remained unchanged, suggesting
that the population had stopped to evolve under the selection
pressure. Indeed, the pool at round 6 was enriched for peptides
displayed on the surface of bacteria that preferentially bind to
A549 cells (Figure 1B). Sixty individual clones of bacteria from this
pool were chosen and grown for the next step of analysis.
2. Identification of Monoclonal Peptide-fluorescent
Bacteria with High Binding Efficiency
The monoclonal peptide-fluorescent bacteria with high binding
efficiency were identified from 60 clones for further experiments.
Before the clones were sent for sequencing, we used FACS to
compare the binding efficiency of bacteria to HLF and A549 cells.
After incubation with induced monoclonal peptide-fluorescent
bacteria, the percentage of the fluorescent cells to whole cells
represented the binding rate of peptides on the surface of clonal
bacteria with cells. The results indicated that the binding rate of all
the bacteria from those 60 clones was around 10%–80% for the
A549 cells, while it was less than 5% for HLF cells (data not
shown). Comparing to those with 20% binding rate, peptides-
fluorescent bacteria with 80% binding rate might have higher
affinity to cells. The binding rate of the monoclonal peptide-
fluorescent bacteria (clone 4) with the highest binding efficiency
was 80% for A549 cells and 0.4% for HLF cells (Figure 2). The
sequencing results showed that seven unique clone sequences were
obtained from 60 clones (Table 1). There was no conserved
sequence observed for all these clones.
3. Evaluation of the Binding Specificity of the Monoclonal
Peptide-fluorescent Bacteria
The identification of a small set of peptide-fluorescent bacteria
that may distinguish the A549 cells from the HLF cells raises a
question of whether these peptide-fluorescent bacteria may bind as
well with other cell types. For this aim we determined to examine
the relative binding potential of all the peptide-fluorescent bacteria
to several cell lines. We first determined the cell type specificity by
measuring the binding activity of all the peptide-fluorescent
bacteria on a panel of unrelated cell lines. We found that any of
the seven peptide-fluorescent bacteria did not bind to other human
Figure 3. The results of selected monoclonal peptide-fluorescent bacteria specifically binding with various cells. (A) Fluorescence
microscope images of bacteria clones incubated with cells. A549g was incubated with CPX only bacteria and other cells were incubated with selected
monoclonal peptide-fluorescent bacteria, the scale bar was 20 mm. (B) FACS results of various cells binding with monoclonal peptide-fluorescent
bacteria at ratio 1:100. (C) Percentage of binding fraction of monoclonal peptide-fluorescent bacteria with various cells from FACS data. Data were
mean 6 S.D. of at least three independent experiments.
doi:10.1371/journal.pone.0054467.g003
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carcinoma cell types including liver (HepG-2), laryngeal (Hep-2),
cervical (Hela) and breast (MCF-7) carcinoma cells. The results
from the observation of fluorescent microscope and flow cytometer
on attached and detached cells verified the binding specificity of
the peptide-fluorescent bacteria. Figure 3 showed the typical
results of the peptide-fluorescent bacteria which had the highest
binding efficiency to A549 cells (clone 4). Furthermore, the
bacteria with only the CPX scaffold protein could not bind with
A549 cells, which meant peptides presenting on the surface of the
bacteria mediated the binding event between bacteria and A549
cells. More attention needs to be paid to other lung carcinoma
cells e.g., H460. Our results illustrated that the monoclonal
peptide-fluorescent bacteria could not recognize H460 cells –
another cell line also belonging to the category of non-small-cell
lung cancer, which implied that the monoclonal peptide-fluores-
cent bacteria have the possibility of recognizing different genres of
lung cancer cells.
4. Maintenance of Binding Ability of Peptide-fluorescent
Bacteria with Tumor Cells for Clinical Application
One fixation method was needed to maintain the binding
specificity and efficiency of bacteria to cells for more extensive
applications. Through comparing the binding effect of bacteria
with cells after bacteria were fixed by ethanol, methanol, acetone
and 4% paraformaldehyde, we chose paraformaldehyde as the
fixation reagent for further study. Although the fixed bacteria still
kept the ability to bind with cells, the binding efficiency of fixed
bacteria was lower than that of fresh bacteria. For obtaining a
comparable binding effect for the fixed bacteria, we increased the
ratio of bacteria to cells from 100:1 to 500:1. The results shown in
Figure 4A and S1 indicated that fixed bacteria still maintained the
binding specificity. Moreover, after comparison with negative
control cells, non-tumor cell line (HLF) with some tumor cell lines
(H460 and Hep-2), the binding specificity of fixed bacteria was
better than that of fresh bacteria. Subsequently, we examined the
change on the binding efficiency of fixed bacteria following the
time lapse. In this experiment, the objectives we chose were fresh
bacteria, freshly fixed bacteria (day 1) and fixed bacteria stored for
7 days and 30 days. The results (Figure 4B, 4C and 4D) showed
that the fixed bacteria still kept a higher binding efficiency with
cells even after being stored for 30 days, which indicated that fixed
fluorescent bacteria could be used to detect A549 cells even after
being stored for quite a long time.
5. Detection of A549 Tumor Tissue from the mice
Xenograft with Peptide-fluorescent Bacteria
After incubated tumor tissue in the A549 mice xenograft with
induced monoclonal peptide-fluorescent bacteria (clone 4 and
CPX only), tumor section in the xenograft emitted green
fluorescence because peptides on the surface of fluorescent
bacteria could recognize the tumor cells. However, tissue section
adjacent to the tumor part incubated with clone 4 peptide-bacteria
and tumor section incubated with CPX only bacteria did not emit
fluorescence signals (Figure 5). These results could be reproduced
with fixed peptide-fluorescent bacteria (data not shown).
Discussion
In our study, specific binding peptides for lung cancer cells were
identified with bacteria surface display method. There were no
conserved sequences for those peptides which indicated that those
peptides might interact with different proteins on the surface of
Figure 4. Characterization of binding ability of fixed bacteria. (A) Percentage of binding fraction of fresh and fixed monoclonal peptide-
fluorescent bacteria with various cells from FACS data. Cells binding to fresh bacteria (black) at ratio 1:100 and binding to fixed bacteria (gray) at ratio
1:500. (B) The fluorescence microscope images of A549 cells incubating with fresh bacteria and fixed bacteria at ratio 1:500, at day 1, day 7 and day 30
after fixation and the scale bar was 20 mm. (C) FACS results of A549 cells binding with fresh and fixed monoclonal peptide-fluorescent bacteria at
ratio 1:500 at different time points. (D) Percentage of binding fraction of fresh and fixed monoclonal peptide-fluorescent bacteria with A549 cells
from FACS data Cells binding with fresh bacteria and fixed bacteria at ratio 1:500 at different time points. Data were mean 6 S.D. of at least three
independent experiments.
doi:10.1371/journal.pone.0054467.g004
Figure 5. The representative images of selected peptide-fluorescent bacteria binding with tissue sections from the mice xenograft.
The scale bar was 20 mm. Data were representative of at least three independent experiments.
doi:10.1371/journal.pone.0054467.g005
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tumor cells. Although those peptides might be used as target
molecules for diagnosis and treatment for cancers, in this study, we
tried to explore the potential of fluorescent E. coli MC1061, which
had specific peptides on the surface, directly worked as diagnostic
reagents. The results from the in vitro experiment indicated that the
selected bacteria with peptides on the surface could specifically
bind with A549 cells with high affinity, regardless if the cells were
attached or detached. The ability of peptide-fluorescent bacteria to
recognize certain tumor cells was confirmed by mice tumor
xenograft experiments. With the results from the in vitro experi-
ments, a novel method was developed for the first time to detect
lung cancer cells directly with fluorescent bacteria. Considering
the shelf time and safety of bacteria, manipulation of live bacteria
was necessary for their further application. Through comparing
the effect of different fixation reagents (ethanol, methanol, acetone
and 4% paraformaldehyde), 4% paraformaldehyde was selected as
the best fixation reagent. The bacteria fixed with this reagent
could maintain a high binding efficiency and specificity to cells for
at least one month.
In the clinical practice and bench work, most of time, imaging
technology was used for diagnosis of lung cancer. Many imaging
molecules already have clinical and sub-clinical usage, for
examples, functional radioactive molecules for PET imaging
[26], novel magnetic materials for MRI imaging [27], new
materials for ultrasonic imaging [28] and PET/MRI imaging [29].
Even there are already reports about the bacterium as a
bioluminescent imaging reagent in diagnosis [30], but its
application was limited due to the scarcity of the precision,
sensitivity and luminescent strength of this imaging reagent. Our
new system can help us not only to discriminate lung cancer cells
from other cells, but also to determine the genre of lung cancer
cells, which makes this method more accurate for diagnosis. At
present, methods that are used clinically to determine the genre of
cells include Hematoxylin and eosin stain (H&E stain) [31] and
immunohistochemistry [32], but these two methods are more
complicated, costly and subjective compared with our new
method. With low investment (only one fluorescent microscope
needed) and short preparation time of samples, our method
provides a new supplementary way for making rapid and accurate
decisions about whether tumors are benign or malignant, where is
the edge of tumor section and even what genre of tumor the
patient has during surgical operations [33,34].
Our study presented a new method to detect lung cancer cells
directly with peptide-fluorescent bacteria as luminescent reagents
in vitro. This method has the advantages of low cost, ease of
procurement, ease of performance, short time preparation and
objectivity. However, currently we could not elucidate the detailed
molecular mechanism about the binding event between peptides
and cells. Moreover, we still need more clinical samples to confirm
the validity of our system. Even though, from the present
experimental results, we believe that this method has huge
potential as a new clinical diagnostic means. In future study,
support from mass experimental data is needed to promote the
translation of this method from the bench to the clinic.
Supporting Information
Figure S1 FACS results of various cells binding with
fixed monoclonal peptide-fluorescent bacteria at ratio
1:500.
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